The global preclinical imaging market size was around USD 866.56 Mn in 2022 and is likely to reach USD 1352.4 Mn by 2031, expanding at a CAGR of 5.08% during 2023–2031. The market growth is attributed to the technological advancement in molecular imaging, the rising number of pharmaceutical companies & clinical research organizations, and a growing number of pre-clinical imaging systems in vivo research.
Preclinical imaging is the visualization of living animals for research purposes. Imaging modalities are used to observe changes in cells, organs, molecular level, and tissue in animals responding to environmental and psychological changes. Small animal models are used in basic and preclinical sciences and are the main keystone for research and development strategies.
Preclinical imaging techniques help in decreasing biological variability and the opportunity to acquire a large amount of information. Preclinical imaging helps to understand the underlying mechanism of diseases, and provides unique and efficient tools for the evaluation of new chemical entities and candidate drugs.
Multimodal molecular imaging plays an important role in the clinical care of different diseases by improving clinicians’ ability to perform staging, screening, planning and therapy guidance, surveillance, prognosis, assessing reassurance, and monitoring therapy efficacy.
The research report finds that the COVID-19 pandemic negatively impacted several industries and the lifestyle of people. Coronavirus disease shut down economics, closed borders, and spread misery on a global scale. However, the pandemic has positive impact on hospitals and clinics, as it increases the hospital capacity for patients diagnosed with coronavirus disease.
The pandemic had a considerable influence on the preclinical imaging market, due to the rising preclinical research studies and activities to test the safety and efficacy of clinical trials. Various companies, researchers, and the government boosted the demand for clinical trials and preclinical imaging devices. Moreover, immunomodulators, anticoagulants, antivirals, and other medicines are in high demand, as they act as a roadmap to prioritize compounds for clinical testing.
In April 2020, the National Institutes of Health announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, to promote a coordinated research strategy and to develop promising treatments and vaccines.
Preclinical Imaging Market Dynamics
Rising funding for supporting preclinical research is anticipated to boost market growth during the forecast period. Growing demand for non-invasive animal imaging techniques is projected to propel the market expansion in the coming years. Moreover, the rapid growth of the research and development sector is a major factor spurring market growth.
Rising adoption of computerized research models, lesser research developments, and strict rules and regulations imposed by the government, which protect animal rights are major factors hampering the market growth. Furthermore, high implementation cost in preclinical imaging and a lack of skilled research personnel is expected to hamper the market in the coming years.
R&D investment and technological advancement in the preclinical imaging market are projected to offer immense opportunities for the market players. Growing demand for non-invasive small animal imaging techniques is expected to create lucrative opportunities in the coming years.
Scope of Preclinical Imaging Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Preclinical Imaging Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Modality (Micro-MRI, Micro-CT, Micro-ultrasound, Nuclear Imaging Systems, Optical Imaging Systems, Photoacoustic Imaging Systems, and Others), Application (Drug Discovery and Research & Development), End-user (Research Institutes, Pharmaceutical Companies, and Biotechnology Companies), and Reagent (PET Tracers, Contrast Agents, Optical Imaging Reagents, and SPECT Probes)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
Key Players Covered in the Report
Agilent Technologies, Inc.; Bruker Corporation; MILabs B.V.; Siemens; Medico Ltd.; General Electric; VisualSonics, Inc.; PerkinElmer, Inc.; and TriFoil Imaging
Preclinical Imaging Market Segment Insights
Modality Segment Analysis
On the basis of modality, the market is segmented into micro-MRI, micro-CT, micro-ultrasound, nuclear imaging systems, optical imaging systems, photoacoustic imaging systems, and others. The micro-ultrasound segment is projected to expand at a considerable CAGR during the forecast period, due to the high usage of micro-ultrasound imaging systems in preclinical research studies around the world.
Micro-ultrasound is important for imaging modality for research and studies in developmental biology, cardiovascular diseases, and cancer. It is highly used for assessing placental, maternal, morphology, and hemodynamics, as well as for image-guided teratology and utero interventions.
Micro-ultrasound helps to study the normal development and models of human diseases in small animals. It helps the researcher to know the physiological, cellular, and molecular changes in animals and to anticipate the outcome of different new treatments in patients.
The nuclear imaging systems segment is anticipated to account for a major market share during the forecast period. Nuclear imaging systems are used to administrate a small amount of radioactivity in the human body. It produces a pictorial representation of metabolic processes by detecting radiation from various parts of the body.
Application Segment Analysis
Based on application, the preclinical imaging market is divided into drug discovery and research & development. The drug discovery segment is expected to hold a significant share of the market in the coming years. In drug discovery, preclinical trials are conducted by researchers in vitro and in vivo with unrestricted dosages.
Preclinical imaging is used to identify new druggable targets, evaluate biodistribution and appropriate dosing strategies, test efficacy and off-targets, and select appropriate patient cohorts for initial testing.
The research & development segment accounts for a significant market share, as preclinical imaging aids in phenotyping, drug discovery, and in providing a basic understanding of the mechanism of diseases. Preclinical imaging aid in observing changes, at the cell, tissue, organ, or molecular level as animals respond to physiological or environmental changes.
End-User Segment Analysis
On the basis of end-user, the global market is segregated into research institutes, pharmaceutical companies, and biotechnology companies. The research institutes segment is anticipated to expand at a substantial CAGR during the forecast period. Preclinical imaging is a strategic technology. It is used to support preclinical research and biopharmaceutical development.
The biotechnology companies segment is expected to hold a significant share of the market. Preclinical imaging is a useful method in research and it involves animals to find out effective procedures, drugs, or treatments. Biotechnology companies test new drugs on animals, before testing on human beings. This is the important stage of the development of new drugs.
Reagent Segment Analysis
Based on reagent, the market is segmented into PET tracers, contrast agents, optical imaging reagents, and SPECT probes. The PET tracers segment is projected to register a considerable share of the market in the coming years.
PET radiotracer is a position-emitting radiopharmaceutical (PET) that is generally used in positron emission tomography. A common radiotracer is F-18 fluorodeoxyglucose (FDG), a molecule similar to glucose. This radiotracer consists of a positron-emitting isotope bound to an organic ligand.
The optical imaging reagents segment is expected to hold a substantial CAGR. Optical imaging reagents are important for the diagnosis and monitoring of oncological, cardiovascular, neurological, and numerous other types of disease. Optical imaging reagents are forms of gallium, fluorine, technetium, xenon, galium, indium, and iodine for use with SPECT.
In terms of regions, the global preclinical imaging market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the forecast period, owing to a well-established player, rising funding to support preclinical research, technological advancements in the field of molecular imaging, and rising market demand for non-invasive small animal imaging techniques.
The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to less stringent regulatory guidelines, low research costs, and increased government funding for the development of the research sector in the respective countries. Moreover, the preclinical research outsourcing industry is growing in developing countries including India and China.
The global preclinical imaging market has been segmented on the basis of
- Nuclear Imaging Systems
- Optical Imaging Systems
- Photoacoustic Imaging Systems
- Drug Discovery
- Research & Development
- Research Institutes
- Pharmaceutical Companies
- Biotechnology Companies
- PET Tracers
- Contrast Agents
- Optical Imaging Reagents
- SPECT Probes
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
Key players competing in the global preclinical imaging market are Agilent Technologies, Inc.; Bruker Corporation; MILabs B.V.; Siemens; Medico Ltd.; General Electric; VisualSonics, Inc.; PerkinElmer, Inc.; and TriFoil Imaging.
Some of the major companies in the market have adopted various organic growth strategies including product launches, mergers, partnerships, and collaborations to increase their market share and witness significant growth. Key players are actively engaged in R&D programs and aim at the expansion of manufacturing units to expand their consumer base and increase their product portfolio.
- In October 2020, MR Solutions a leading company based in UK, received a purchase order for their preclinical devices of up to USD 10 million from top universities. PET/CTs, PET/MRs, and 9.4T and 7T cryogen-free DRY magnets were the top sellers, among market players.
- In May 2022, Bruker launched innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets for its market-leading preclinical magnetic resonance imaging (MRI) systems portfolio.
- In April 2022, PerkinElmer announced the expansion of its in vivo imaging portfolio with the launch of the Vega imaging system, a first-of-its-kind ultrasound platform that combines hands-free, automated technology with the high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology and more.